# Apixaban for the Prevention of Latent Biological Valve Thrombosis

> **NCT06184113** · PHASE4 · UNKNOWN · sponsor: **Clinical Hospital Centre Zagreb** · enrollment: 166 (estimated)

## Conditions studied

- Aortic Valve Replacement
- Antithrombotic Therapy
- Bioprosthetic Valve Thrombosis
- Rapid Deployment Valves

## Interventions

- **PROCEDURE:** Aortic valve replacement surgery
- **DIAGNOSTIC_TEST:** Computed tomography
- **DIAGNOSTIC_TEST:** Echocardiography

## Key facts

- **NCT ID:** NCT06184113
- **Lead sponsor:** Clinical Hospital Centre Zagreb
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 166 (ESTIMATED)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06184113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06184113, "Apixaban for the Prevention of Latent Biological Valve Thrombosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06184113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*